Cord Blood America to complete its new Las Vegas laboratory on schedule

Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, said today that it is on schedule to complete the construction of its new Las Vegas laboratory by the first week of October.

Matthew Schissler, founder and CEO, was interviewed by analyst Francis Gaskins. The entire interview is available at http://www.stoxrox.com/cbai-9-10-09.mp3 .

"Most of the equipment has been purchased and we are scheduled to begin processing our own stem cells in the near future," Mr. Schissler said in the interview. He said the new laboratory will:

• Allow gross profit to increase greatly because the Company will no longer outsource and pay significant storage fees.
• Allow Cord Blood to store tissues and samples for other companies.
• Decrease transportation costs because the lab is near the large Las Vegas airport.
• Allow for the storage of other stem cells such as adipose tissue and peripheral blood stem cells.
• Prepare the Company for the future, with more medical uses of stem cells expected every year.

"This facility will perhaps be the largest cryogenic storage lab in the U.S. We believe adding business-to-business clients, and diversifying our income stream, will provide immediate returns for shareholders," Mr. Schissler said.

In the interview, Cord Blood America's CEO said $6.6 million in debt has been eliminated from the balance sheet so far this year and "we will continue to reduce debt as far and fast as possible. Shareholders should understand that once the debt is gone, the true valuation of the Company will emerge."